• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506

• Triterpenoids

Cucurbitacin E 2-O-Glucoside (Elaterinide) and Its Significance in Modern Research

Cucurbitacin E 2-O-Glucoside (Elaterinide), with the CAS number 1398-78-3, is a naturally occurring triterpenoid glycoside that has garnered significant attention in the field of pharmaceutical research and development. This compound, derived from the Cucurbitaceae family of plants, exhibits a unique chemical structure that has positioned it as a promising candidate for various therapeutic applications. The glucosidic modification of Cucurbitacin E enhances its solubility and bioavailability, making it more suitable for clinical use compared to its aglycone form.

The pharmacological properties of Cucurbitacin E 2-O-Glucoside (Elaterinide) have been extensively studied, particularly for its potential in cancer therapy. Recent research has highlighted its ability to induce apoptosis in cancer cells by modulating multiple signaling pathways. Specifically, studies have demonstrated that this compound can activate caspase-dependent and caspase-independent apoptosis pathways, leading to the selective death of tumor cells while sparing healthy cells. This selective toxicity is attributed to its ability to disrupt the mitochondrial membrane potential and trigger the release of pro-apoptotic proteins.

In addition to its anti-cancer properties, Cucurbitacin E 2-O-Glucoside (Elaterinide) has shown promise in the treatment of inflammatory diseases. Emerging evidence suggests that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 by suppressing nuclear factor kappa B (NF-κB) activation. This mechanism not only reduces inflammation but also has implications for the development of novel anti-inflammatory therapies. The compound's ability to modulate immune responses makes it a valuable candidate for further investigation in autoimmune disorders.

The structural features of Cucurbitacin E 2-O-Glucoside (Elaterinide) contribute to its unique biological activity. The glucosidic moiety enhances its interaction with biological targets, improving its pharmacokinetic profile. This modification also increases its stability in biological systems, allowing for more effective delivery and action. The compound's solubility in water makes it particularly suitable for oral and intravenous administration, which could facilitate its clinical translation.

Recent advancements in synthetic chemistry have enabled the scalable production of Cucurbitacin E 2-O-Glucoside (Elaterinide), making it more accessible for preclinical and clinical studies. Researchers have developed efficient synthetic routes that minimize side reactions and maximize yield, ensuring a consistent supply of high-quality material. These improvements are crucial for conducting rigorous pharmacological studies and ultimately bringing this promising compound into clinical trials.

The potential therapeutic applications of Cucurbitacin E 2-O-Glucoside (Elaterinide) extend beyond oncology and inflammation. Preliminary studies have explored its effects on neurodegenerative diseases, suggesting that it may protect against neuronal damage by inhibiting oxidative stress and promoting neurogenesis. Additionally, its anti-microbial properties have been investigated, with findings indicating that it can disrupt bacterial cell membranes and inhibit bacterial growth. These diverse biological activities highlight the compound's broad therapeutic potential.

The future direction of research on Cucurbitacin E 2-O-Glucoside (Elaterinide) includes elucidating its exact mechanisms of action and identifying optimal dosing regimens for different therapeutic indications. Combination therapies involving this compound with other drugs are also being explored to enhance efficacy and reduce side effects. As our understanding of its pharmacology grows, so does the likelihood that it will play a significant role in the treatment of various diseases.

In conclusion, Cucurbitacin E 2-O-Glucoside (Elaterinide) is a multifaceted compound with significant potential in pharmaceutical applications. Its unique chemical structure and biological activities make it a valuable asset in the fight against cancer, inflammation, and other diseases. With ongoing research and development efforts, this compound is poised to make a substantial impact on modern medicine.

• 99132-97-5(methyl (11beta,12alpha,13xi,15beta)-3-(beta-D-glucopyranosyloxy)-11,12-dihydroxy-15-{[(2E)-4-hydroxy-3,4-dimethylpent-2-enoyl]oxy}-2,16-dioxo-13,20-epoxypicras-3-en-21-oate)
• 119626-74-3(19-Norlanosta-1,5,23-triene-3,22-dione,16-[(2,4-di-O-acetyl-a-L-arabinopyranosyl)oxy]-2,20,25-trihydroxy-9-methyl-, (9b,10a,16a,23E)-)
• 112899-35-1(Picras-2-en-21-oicacid,15-[[(2E)-4-(acetyloxy)-3,4-dimethyl-1-oxo-2-penten-1-yl]oxy]-13,20-epoxy-2-(b-D-glucopyranosyloxy)-11,12-dihydroxy-1,16-dioxo-,methyl ester, (11b,12a,15b)-)
• 101559-98-2(Picras-3-en-21-oicacid,15-[[(2E)-4-(acetyloxy)-3,4-dimethyl-1-oxo-2-pentenyl]oxy]-13,20-epoxy-3-(b-D-glucopyranosyloxy)-11,12-dihydroxy-2,16-dioxo-,methyl ester, (11b,12a,15b)- (9CI))
• 167782-24-3(Picras-1-en-21-oicacid,15-[[(2E)-4-(acetyloxy)-3,4-dimethyl-1-oxo-2-penten-1-yl]oxy]-13,20-epoxy-2-(b-D-glucopyranosyloxy)-11,12-dihydroxy-3,16-dioxo-,(11b,12a,15b)-)
• 95258-16-5(methyl (11beta,12alpha,13xi,15beta)-2-(beta-D-glucopyranosyloxy)-11,12-dihydroxy-15-{[(2E)-4-hydroxy-3,4-dimethylpent-2-enoyl]oxy}-3,16-dioxo-13,20-epoxypicras-1-en-21-oate)
• 1236034-79-9((4R,9beta,16alpha,24S)-20-hydroxy-9,10,14-trimethyl-1,11,22-trioxo-16,24-epoxy-4,9-cyclo-9,10-secochloesta-2,5,25-trien-2-yl beta-D-glucopyranoside)
• 95258-17-6(methyl (11beta,12alpha,13xi,15beta)-15-{[(2E)-4-(acetyloxy)-3,4-dimethylpent-2-enoyl]oxy}-2-(beta-D-glucopyranosyloxy)-11,12-dihydroxy-3,16-dioxo-13,20-epoxypicras-1-en-21-oate)
• 119626-75-4(19-Norlanosta-1,5,23-triene-3,22-dione, 16-[(2-O-acetyl-α-L-arabinopyranosyl)oxy]-2,20,25-trihydroxy-9-methyl-, (9β,10α,16α,23E)-)
• 29803-94-9(19-Norlanosta-1,5,23-triene-3,11,22-trione,2-(b-D-glucopyranosyloxy)-16,20,25-trihydroxy-9-methyl-,(9b,10a,16a,23E)-)